HAUPPAUGE, N.Y.--(BUSINESS WIRE)--TSR, Inc. (Nasdaq: TSRI), a leading provider of computer programming consulting services (“TSR” or the “Company”), today announced that its Board of Directors has ...
TSR-042 is the first TESARO immuno-oncology candidate to enter a registration program Ongoing clinical trial expanded to enroll patients with endometrial cancer Patient-centric administration schedule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results